Work

Saraswata Ghrita mitigates AlCl₃- and D-galactose–induced cognitive deficits in a murine Alzheimer’s-like model: In silico and in vivo insights

Year: 2026

Type: article

Abstract: BACKGROUND: Alzheimer's disease (AD) is characterized by cognitive decline linked to cholinergic dysfunction, oxidative stress, and neuroinflammation. Saraswata Ghrita (SG), a classical Ayurvedic formulation, was evaluated using an integrated in silico-in vivo workflow focusing on acetylcholinesterase (AChE) and related pathways. METHODS: SG constituents were profiled by GC-MS/MS and HR-LCMS/MS-QTOF. BBB-permeable, drug-like candidates were prioritized (SwissADME/BOILED-Egg) and evaluated by docking and molecular dynamics. In vivo, mice received AlCl₃ (4 mg/kg, i.p.) + D-galactose (50 mg/kg, i.p.) for 60 days; SG (3, 6, 12 mL/kg, p.o.) or donepezil (0.5 mg/kg, i.p.) was administered on days 31-60. Behavioral, biochemical, and histological endpoints were assessed (n = 6/group). RESULTS: In silico, LIG_91 showed the top predicted AChE binding affinity (-8.5 kcal·mol⁻¹) and LIG_212 scored -7.8 kcal·mol⁻¹ (supportive evidence). AlCl₃+D-galactose impaired cognition (MWM day-4 ELT 85.8 ± 5.3 s; TSTQ 34.6 ± 2.2 s). SG 12 mL/kg improved MWM performance (ELT 44.1 ± 3.2 s, ∼49 % lower vs model; TSTQ 50.1 ± 2.8 s, ∼45 %higher), while donepezil produced greater improvement (ELT 26.7 ± 2.4 s, ∼69 % lower; TSTQ 58.1 ± 5.4 s, ∼68 %higher). SG 12 mL/kg reduced oxidative stress (TBARS 12.93 ± 1.58 → 8.84 ± 0.52 nM/mg, ∼32 % decrease) and improved antioxidant status (GSH 7.52 ± 0.48 → 11.10 ± 0.48 µM/mg, ∼48 % increase). SG also attenuated neuroinflammation (IL-6 211.1 ± 10.6 → 165.0 ± 23.6 pg/mL, ∼22 % decrease; TNF-α 179.3 ± 8.7 → 133.7 ± 7.8 pg/mL, ∼25 % decrease; IL-10 12.3 ± 1.0 → 30.2 ± 5.2 pg/mL, ∼146 % increase) and lowered AChE activity (10.61 ± 0.61 → 8.49 ± 0.49 µM/min/mg, ∼20 % decrease). H&E micrographs qualitatively suggested reduced cortical neuronal degeneration. CONCLUSIONS: SG administration was associated with improved cognition and partial normalization of cholinergic, oxidative, and inflammatory markers in this model. Computational findings support possible AChE engagement but are not definitive; further quantitative histology and standardized-formulation studies are warranted.

Source: Brain Research Bulletin

DOI: 10.1016/j.brainresbull.2026.111742